ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Drugs for Oncology Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-36O5754
Home | Market Reports | Health| Health Foundations & Medical Research
Global Drugs for Oncology Market Insights Forecast to 2028
BUY CHAPTERS

Global Drugs for Oncology Market Research Report 2025

Code: QYRE-Auto-36O5754
Report
July 2025
Pages:102
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Celgene
Novartis
Bristol–Myers Squibb
Johnson & Johnson
Merck
Astrazeneca plc
Pfizer Inc
Amgen Inc
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen S A
Sanofi
Bayer
Biogen Idec
TEVA
Otsuka
Eisai Co Ltd
Merck KGaA
Gilead Sciences
Johnson & Johnson

Drugs for Oncology Market Size

The global market for Drugs for Oncology was valued at US$ 231130 million in the year 2024 and is projected to reach a revised size of US$ 393180 million by 2031, growing at a CAGR of 8.0% during the forecast period.

Drugs for Oncology Market

Drugs for Oncology Market

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.
When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.
Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.
Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Drugs for Oncology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Oncology.
The Drugs for Oncology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Drugs for Oncology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Oncology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Drugs for Oncology Market Report

Report Metric Details
Report Name Drugs for Oncology Market
Accounted market size in year US$ 231130 million
Forecasted market size in 2031 US$ 393180 million
CAGR 8.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Drugs for Oncology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Drugs for Oncology Market growing?

Ans: The Drugs for Oncology Market witnessing a CAGR of 8.0% during the forecast period 2025-2031.

What is the Drugs for Oncology Market size in 2031?

Ans: The Drugs for Oncology Market size in 2031 will be US$ 393180 million.

Who are the main players in the Drugs for Oncology Market report?

Ans: The main players in the Drugs for Oncology Market are Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer, Amgen, Eli Lilly, AbbVie, Takeda, Astellas, Ipsen, Sanofi, Bayer, Biogen Idec, Teva, Otsuka, Eisai, Merck KGaA, Gilead Sciences

What are the Application segmentation covered in the Drugs for Oncology Market report?

Ans: The Applications covered in the Drugs for Oncology Market report are Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Others

What are the Type segmentation covered in the Drugs for Oncology Market report?

Ans: The Types covered in the Drugs for Oncology Market report are Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others

Recommended Reports

Oncology Drug Markets

Cancer Therapy Innovations

Targeted & Molecular Oncology

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Drugs for Oncology Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Oncology Market Perspective (2020-2031)
2.2 Global Drugs for Oncology Growth Trends by Region
2.2.1 Global Drugs for Oncology Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Drugs for Oncology Historic Market Size by Region (2020-2025)
2.2.3 Drugs for Oncology Forecasted Market Size by Region (2026-2031)
2.3 Drugs for Oncology Market Dynamics
2.3.1 Drugs for Oncology Industry Trends
2.3.2 Drugs for Oncology Market Drivers
2.3.3 Drugs for Oncology Market Challenges
2.3.4 Drugs for Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Oncology Players by Revenue
3.1.1 Global Top Drugs for Oncology Players by Revenue (2020-2025)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2020-2025)
3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Drugs for Oncology Revenue
3.4 Global Drugs for Oncology Market Concentration Ratio
3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2024
3.5 Global Key Players of Drugs for Oncology Head office and Area Served
3.6 Global Key Players of Drugs for Oncology, Product and Application
3.7 Global Key Players of Drugs for Oncology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Oncology Breakdown Data by Type
4.1 Global Drugs for Oncology Historic Market Size by Type (2020-2025)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2026-2031)
5 Drugs for Oncology Breakdown Data by Application
5.1 Global Drugs for Oncology Historic Market Size by Application (2020-2025)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Drugs for Oncology Market Size (2020-2031)
6.2 North America Drugs for Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Drugs for Oncology Market Size by Country (2020-2025)
6.4 North America Drugs for Oncology Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Oncology Market Size (2020-2031)
7.2 Europe Drugs for Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Drugs for Oncology Market Size by Country (2020-2025)
7.4 Europe Drugs for Oncology Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Oncology Market Size (2020-2031)
8.2 Asia-Pacific Drugs for Oncology Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Drugs for Oncology Market Size by Region (2020-2025)
8.4 Asia-Pacific Drugs for Oncology Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Oncology Market Size (2020-2031)
9.2 Latin America Drugs for Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Drugs for Oncology Market Size by Country (2020-2025)
9.4 Latin America Drugs for Oncology Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Oncology Market Size (2020-2031)
10.2 Middle East & Africa Drugs for Oncology Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Drugs for Oncology Market Size by Country (2020-2025)
10.4 Middle East & Africa Drugs for Oncology Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Drugs for Oncology Introduction
11.1.4 Roche Revenue in Drugs for Oncology Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Details
11.2.2 Celgene Business Overview
11.2.3 Celgene Drugs for Oncology Introduction
11.2.4 Celgene Revenue in Drugs for Oncology Business (2020-2025)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Drugs for Oncology Introduction
11.3.4 Novartis Revenue in Drugs for Oncology Business (2020-2025)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Details
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Drugs for Oncology Introduction
11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2020-2025)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Details
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Drugs for Oncology Introduction
11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2020-2025)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drugs for Oncology Introduction
11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2020-2025)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Drugs for Oncology Introduction
11.8.4 Pfizer Revenue in Drugs for Oncology Business (2020-2025)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Drugs for Oncology Introduction
11.9.4 Amgen Revenue in Drugs for Oncology Business (2020-2025)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Details
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Drugs for Oncology Introduction
11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2020-2025)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Drugs for Oncology Introduction
11.11.4 AbbVie Revenue in Drugs for Oncology Business (2020-2025)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Details
11.12.2 Takeda Business Overview
11.12.3 Takeda Drugs for Oncology Introduction
11.12.4 Takeda Revenue in Drugs for Oncology Business (2020-2025)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Details
11.13.2 Astellas Business Overview
11.13.3 Astellas Drugs for Oncology Introduction
11.13.4 Astellas Revenue in Drugs for Oncology Business (2020-2025)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Details
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Drugs for Oncology Introduction
11.14.4 Ipsen Revenue in Drugs for Oncology Business (2020-2025)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Details
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Drugs for Oncology Introduction
11.15.4 Sanofi Revenue in Drugs for Oncology Business (2020-2025)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Details
11.16.2 Bayer Business Overview
11.16.3 Bayer Drugs for Oncology Introduction
11.16.4 Bayer Revenue in Drugs for Oncology Business (2020-2025)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Details
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Drugs for Oncology Introduction
11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2020-2025)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Details
11.18.2 Teva Business Overview
11.18.3 Teva Drugs for Oncology Introduction
11.18.4 Teva Revenue in Drugs for Oncology Business (2020-2025)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Details
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Drugs for Oncology Introduction
11.19.4 Otsuka Revenue in Drugs for Oncology Business (2020-2025)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Details
11.20.2 Eisai Business Overview
11.20.3 Eisai Drugs for Oncology Introduction
11.20.4 Eisai Revenue in Drugs for Oncology Business (2020-2025)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Details
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Drugs for Oncology Introduction
11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2020-2025)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Details
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Drugs for Oncology Introduction
11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2020-2025)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Roche
Celgene
Novartis
Bristol–Myers Squibb
Johnson & Johnson
Merck
Astrazeneca plc
Pfizer Inc
Amgen Inc
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen S A
Sanofi
Bayer
Biogen Idec
TEVA
Otsuka
Eisai Co Ltd
Merck KGaA
Gilead Sciences
Johnson & Johnson
List of Tables
 Table 1. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Chemotherapy
 Table 3. Key Players of Targeted Therapy
 Table 4. Key Players of Immunotherapy (Biologic Therapy)
 Table 5. Key Players of Hormonal Therapy
 Table 6. Key Players of Others
 Table 7. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Drugs for Oncology Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global Drugs for Oncology Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global Drugs for Oncology Market Share by Region (2020-2025)
 Table 11. Global Drugs for Oncology Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global Drugs for Oncology Market Share by Region (2026-2031)
 Table 13. Drugs for Oncology Market Trends
 Table 14. Drugs for Oncology Market Drivers
 Table 15. Drugs for Oncology Market Challenges
 Table 16. Drugs for Oncology Market Restraints
 Table 17. Global Drugs for Oncology Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global Drugs for Oncology Market Share by Players (2020-2025)
 Table 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2024)
 Table 20. Ranking of Global Top Drugs for Oncology Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by Drugs for Oncology Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of Drugs for Oncology, Headquarters and Area Served
 Table 23. Global Key Players of Drugs for Oncology, Product and Application
 Table 24. Global Key Players of Drugs for Oncology, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global Drugs for Oncology Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global Drugs for Oncology Revenue Market Share by Type (2020-2025)
 Table 28. Global Drugs for Oncology Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global Drugs for Oncology Revenue Market Share by Type (2026-2031)
 Table 30. Global Drugs for Oncology Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global Drugs for Oncology Revenue Market Share by Application (2020-2025)
 Table 32. Global Drugs for Oncology Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global Drugs for Oncology Revenue Market Share by Application (2026-2031)
 Table 34. North America Drugs for Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America Drugs for Oncology Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America Drugs for Oncology Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe Drugs for Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe Drugs for Oncology Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe Drugs for Oncology Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific Drugs for Oncology Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific Drugs for Oncology Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific Drugs for Oncology Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America Drugs for Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America Drugs for Oncology Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America Drugs for Oncology Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa Drugs for Oncology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa Drugs for Oncology Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa Drugs for Oncology Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Roche Company Details
 Table 50. Roche Business Overview
 Table 51. Roche Drugs for Oncology Product
 Table 52. Roche Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 53. Roche Recent Development
 Table 54. Celgene Company Details
 Table 55. Celgene Business Overview
 Table 56. Celgene Drugs for Oncology Product
 Table 57. Celgene Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 58. Celgene Recent Development
 Table 59. Novartis Company Details
 Table 60. Novartis Business Overview
 Table 61. Novartis Drugs for Oncology Product
 Table 62. Novartis Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 63. Novartis Recent Development
 Table 64. Bristol-Myers Squibb Company Details
 Table 65. Bristol-Myers Squibb Business Overview
 Table 66. Bristol-Myers Squibb Drugs for Oncology Product
 Table 67. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 68. Bristol-Myers Squibb Recent Development
 Table 69. Johnson & Johnson Company Details
 Table 70. Johnson & Johnson Business Overview
 Table 71. Johnson & Johnson Drugs for Oncology Product
 Table 72. Johnson & Johnson Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 73. Johnson & Johnson Recent Development
 Table 74. Merck & Co. Company Details
 Table 75. Merck & Co. Business Overview
 Table 76. Merck & Co. Drugs for Oncology Product
 Table 77. Merck & Co. Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 78. Merck & Co. Recent Development
 Table 79. AstraZeneca Company Details
 Table 80. AstraZeneca Business Overview
 Table 81. AstraZeneca Drugs for Oncology Product
 Table 82. AstraZeneca Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 83. AstraZeneca Recent Development
 Table 84. Pfizer Company Details
 Table 85. Pfizer Business Overview
 Table 86. Pfizer Drugs for Oncology Product
 Table 87. Pfizer Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 88. Pfizer Recent Development
 Table 89. Amgen Company Details
 Table 90. Amgen Business Overview
 Table 91. Amgen Drugs for Oncology Product
 Table 92. Amgen Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 93. Amgen Recent Development
 Table 94. Eli Lilly Company Details
 Table 95. Eli Lilly Business Overview
 Table 96. Eli Lilly Drugs for Oncology Product
 Table 97. Eli Lilly Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 98. Eli Lilly Recent Development
 Table 99. AbbVie Company Details
 Table 100. AbbVie Business Overview
 Table 101. AbbVie Drugs for Oncology Product
 Table 102. AbbVie Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 103. AbbVie Recent Development
 Table 104. Takeda Company Details
 Table 105. Takeda Business Overview
 Table 106. Takeda Drugs for Oncology Product
 Table 107. Takeda Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 108. Takeda Recent Development
 Table 109. Astellas Company Details
 Table 110. Astellas Business Overview
 Table 111. Astellas Drugs for Oncology Product
 Table 112. Astellas Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 113. Astellas Recent Development
 Table 114. Ipsen Company Details
 Table 115. Ipsen Business Overview
 Table 116. Ipsen Drugs for Oncology Product
 Table 117. Ipsen Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 118. Ipsen Recent Development
 Table 119. Sanofi Company Details
 Table 120. Sanofi Business Overview
 Table 121. Sanofi Drugs for Oncology Product
 Table 122. Sanofi Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 123. Sanofi Recent Development
 Table 124. Bayer Company Details
 Table 125. Bayer Business Overview
 Table 126. Bayer Drugs for Oncology Product
 Table 127. Bayer Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 128. Bayer Recent Development
 Table 129. Biogen Idec Company Details
 Table 130. Biogen Idec Business Overview
 Table 131. Biogen Idec Drugs for Oncology Product
 Table 132. Biogen Idec Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 133. Biogen Idec Recent Development
 Table 134. Teva Company Details
 Table 135. Teva Business Overview
 Table 136. Teva Drugs for Oncology Product
 Table 137. Teva Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 138. Teva Recent Development
 Table 139. Otsuka Company Details
 Table 140. Otsuka Business Overview
 Table 141. Otsuka Drugs for Oncology Product
 Table 142. Otsuka Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 143. Otsuka Recent Development
 Table 144. Eisai Company Details
 Table 145. Eisai Business Overview
 Table 146. Eisai Drugs for Oncology Product
 Table 147. Eisai Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 148. Eisai Recent Development
 Table 149. Merck KGaA Company Details
 Table 150. Merck KGaA Business Overview
 Table 151. Merck KGaA Drugs for Oncology Product
 Table 152. Merck KGaA Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 153. Merck KGaA Recent Development
 Table 154. Gilead Sciences Company Details
 Table 155. Gilead Sciences Business Overview
 Table 156. Gilead Sciences Drugs for Oncology Product
 Table 157. Gilead Sciences Revenue in Drugs for Oncology Business (2020-2025) & (US$ Million)
 Table 158. Gilead Sciences Recent Development
 Table 159. Research Programs/Design for This Report
 Table 160. Key Data Information from Secondary Sources
 Table 161. Key Data Information from Primary Sources
 Table 162. Authors List of This Report


List of Figures
 Figure 1. Drugs for Oncology Picture
 Figure 2. Global Drugs for Oncology Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Drugs for Oncology Market Share by Type: 2024 VS 2031
 Figure 4. Chemotherapy Features
 Figure 5. Targeted Therapy Features
 Figure 6. Immunotherapy (Biologic Therapy) Features
 Figure 7. Hormonal Therapy Features
 Figure 8. Others Features
 Figure 9. Global Drugs for Oncology Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global Drugs for Oncology Market Share by Application: 2024 VS 2031
 Figure 11. Blood Cancer Case Studies
 Figure 12. Breast Cancer Case Studies
 Figure 13. Gastrointestinal Cancer Case Studies
 Figure 14. Prostate Cancer Case Studies
 Figure 15. Respiratory/Lung Cancer Case Studies
 Figure 16. Others Case Studies
 Figure 17. Drugs for Oncology Report Years Considered
 Figure 18. Global Drugs for Oncology Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 19. Global Drugs for Oncology Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 20. Global Drugs for Oncology Market Share by Region: 2024 VS 2031
 Figure 21. Global Drugs for Oncology Market Share by Players in 2024
 Figure 22. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2024)
 Figure 23. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2024
 Figure 24. North America Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. North America Drugs for Oncology Market Share by Country (2020-2031)
 Figure 26. United States Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Canada Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Europe Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Europe Drugs for Oncology Market Share by Country (2020-2031)
 Figure 30. Germany Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. France Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. U.K. Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Italy Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Russia Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Nordic Countries Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Asia-Pacific Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Asia-Pacific Drugs for Oncology Market Share by Region (2020-2031)
 Figure 38. China Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Japan Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. South Korea Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. India Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Australia Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Latin America Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Latin America Drugs for Oncology Market Share by Country (2020-2031)
 Figure 46. Mexico Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Brazil Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Middle East & Africa Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. Middle East & Africa Drugs for Oncology Market Share by Country (2020-2031)
 Figure 50. Turkey Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. UAE Drugs for Oncology Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Roche Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 54. Celgene Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 55. Novartis Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 57. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 58. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 59. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 60. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 61. Amgen Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 62. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 63. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 64. Takeda Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 65. Astellas Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 66. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 67. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 68. Bayer Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 69. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 70. Teva Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 71. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 72. Eisai Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 73. Merck KGaA Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 74. Gilead Sciences Revenue Growth Rate in Drugs for Oncology Business (2020-2025)
 Figure 75. Bottom-up and Top-down Approaches for This Report
 Figure 76. Data Triangulation
 Figure 77. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Oncology Drugs Market Insights Forecast to 2030
Global Oncology Therapeutic Drug Market Research Report 2024
Oncology Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oncology Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Tumor Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cell Separation and Characterization in Solid Tumors Market Insights Forecast to 2030
Global Solid Tumor Therapeutics Market Research Report 2024
Global Brain Cancer Targeted Drug Market Research Report 2025
Global Brain Tumor Therapeutics Market Research Report 2024
Global Targeted Therapy for Brain Cancer Market Research Report 2025
Global Solid Tumor Cancer Treatment Market Insights Forecast to 2030
Global Breast Cancer Targeted Drug Market Research Report 2025
Global Rectal Cancer Therapeutics Market Insights Forecast to 2030
Global Oncology Small Molecule Drugs Market Insights Forecast to 2030
Global Tumor Genomics Market Research Report 2024
Global Targeted Therapy for Breast Cancer Market Research Report 2025
Global Prostate Cancer Market Insights Forecast to 2030
Global Breast Cancer Drugs Market Insights Forecast to 2030
Global Brain and Central Nervous System Cancer Treatments Market Research Report 2024
Global Bone Tumor Ablation Devices Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions